Access to Medicines

Health is one of our most important personal assets and medicines play an essential role in preserving it. Yet around the world, millions lack access to comprehensive health care, including medicines and other treatment tools. Lilly is committed to expanding access to medicines, and we work with partners to improve health outcomes for underserved populations.

We recognize that poor disease outcomes—especially among low-income populations—are about more than medicine alone. Meeting patients’ needs is the result of a complex coordination of healthcare tools, healthcare professionals, supporting infrastructure, and appropriate measurement, evaluation, and regulatory capabilities.

In 2011, we launched a new platform to help address these issues, The Lilly Global Health Innovation Campaign. The campaign encompasses two of Lilly’s signature public/private programs, The Lilly NCD Partnership and The Lilly MDR-TB Partnership.

In addition to investing in these public/private partnerships, we use multiple other strategies to help increase access to medicines, including exploring differential pricing for medicines; not enforcing intellectual property rights for Lilly medicines in least-developed countries (LDCs) as defined by the United Nations; and providing donations for PAP on Lilly products through our Lilly TruAssist program and Life for a Child. In times of disaster, we donate medicines to those in need. We also support programs that improve patient outcomes, such as scholarships, award recognitions, and tools for healthy living.

Diabetes is a chronic disease that occurs either when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces. Over time, it leads to serious damage to many of the body's systems. Since 1923, Lilly has been involved in pioneering therapies to help healthcare providers improve the lives of people with diabetes, and research continues on innovative medicines to address the unmet needs of patients.

Estimated number of patients with diabetes was calculated by multiplying the prevalence rate by the population aged 20-79 from IDF's 2009 Diabetes Atlas; "Diabetes Prevalence Rate" and "Estimated Number of Diabetes Patients refer to both Type 1 and II diabetes.
How lilly is
tackling diabetes
across the globe
Select locations to learn how Lilly is helping
Lilly's Partner in Mexico:
Carlos Slim Health Institute

Lilly Mexico will work with (CSHI) and others to help strengthen the diabetes care capabilities at primary healthcare clinics and related healthcare system components.

Learn More

Lilly Camp Care Package

Lilly Diabetes is one of the largest providers of insulin and glucagon, educational materials, volunteers, scholarships, and special guests to diabetes camps through our comprehensive Lilly Camp Care Package program, in partnership with the American Diabetes Association and the Diabetes Education & Camping Association. Lilly Diabetes is dedicated to providing these personalized tools and resources to help children manage everyday experiences with diabetes while they're at camp—and long after.

Learn More

Lilly's Partners in South Africa: Project HOPE, The Donald Woods Foundation

Lilly and Project HOPE's new diabetes program will:

  • Train community health workers at both urban and rural sites to diagnose and refer patients,
  • Launch peer support groups to generate awareness and manage diabetes at the community level, and
  • Strengthen clinic capabilities.

Learn More

Life for a Child

Lilly has committed to donating more than 800,000 vials of insulin to the International Diabetes Federation's Life for a Child program between 2008 and 2013. These donations, initially focused on 12 countries in sub-Saharan Africa, have now expanded to include 21 countries throughout Africa, Asia, and South America. The medicine will help as many as 24,000 children who have no access to diabetes treatment.

Learn More

Lilly's Partners in India:
Public Health Foundation of India, Project
HOPE, Population Services International

Working with our partners, we will implement a comprehensive model for diabetes care, seeking to:

  • Develop diabetes awareness, patient care and provider training in one district in India,
  • Improve treatment access, including oral medications and insulin, and
  • Research program impact, cost-effectiveness and best practices.

Learn More